Pharmaceutical Commerce

Featured Content

The Key to Connecting with Patients: Pharma's Market Access Transformation

Traditional market access practices are being transformed by an increasingly rocky landscape of rebate, discount, and direct-distribution practices, but artificial intelligence may clear the pathways to profitability.

Working with the Middle

How pharma can productively coexist with PBMs—and still lower drug costs faster.

The Next Era of Drug Safety is in Intelligent Action

As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.

Pharmaceutical Commerce - December 2025

Click here to read the articles and view the interactive digital edition

Pharma's Year of Two Halves

February 06, 2026

What 2025 means for the life sciences sector in the New Year.

TrumpRx Launches With MFN-Based Drug Discounts

February 06, 2026

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

The Great Repricing: Commercial Channel Under Pressure

February 06, 2026

The commercial PBM model is confronting structural strain as market forces—not regulation—begin to expose the fragility of high-rebate pricing economics.

Your Copay Program Is Protecting Access. Is It Also Protecting Gross-to-Net?

February 06, 2026

A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026.

Pharma Pulse: PBM Reform Hits the Courtroom and Telehealth’s Legislative Victory

February 06, 2026

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.

What Does Healthcare Look Like for Patients in 2026?

February 05, 2026

Policy shifts bring meaningful improvements for some—but looming coverage losses and rising premiums threaten to erase those gains.

FTC–Express Scripts Settlement Targets PBM Rebates, Transparency, and Patient Drug Costs

February 05, 2026

A landmark FTC settlement requires Express Scripts to overhaul formulary and rebate practices, boosting price transparency in the process.

Flood the Zone with Generous, Globe, and Guard

February 05, 2026

CMS’s Globe and Guard models extend MFN pricing into Medicare Part B and Part D, signaling a sweeping shift in US drug pricing policy.

Why Adaptive Capacity May Define Long-Term Success

February 05, 2026

At Trade & Channel Strategies, industry executives explored evolving channel models, serialization challenges, generics and biosimilars, and the strategies shaping pharma's future.

Pharma Pulse: Transparency Mandates and the Novartis Patent Storm

February 05, 2026

In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, while Novartis braces for the largest patent expiration cycle in its history.